It is well known that PCSK9 gain-of-function mutations cause hypercholesterolemia and premature atherosclerosis [30], and PCSK9 inhibition is an emergent target in the treatment of ischemic heart disease [31]. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.